(Released August 2022) Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) - A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients with COVID-19

This was a prospective observational cohort surveillance study of approximately 1100 adult participants hospitalized with COVID-19. Detailed information was collected regarding patient history and onset of illness upon enrollment. Participants had longitudinal assessments of clinical status, and pertinent clinical data (including clinical laboratory values, radiographic findings, medication use, oxygen and ventilatory support requirements, complications, etc.) was recorded. In parallel, the study conducted serial biologic sampling for detailed immunophenotyping to provide a comprehensive picture of immune changes that occurred throughout the course of infection. The biological samples collected included blood, nasal swabs, and endotracheal aspirates. Participants were followed in hospital through Day 28, unless discharged earlier. If a participant required an escalation to Intensive Care Unit (ICU)-level care, either within or outside of a dedicated ICU, additional samples were collected within 24 and 96 hours of care escalation. Convalescent questionnaires and biological samples were collected at 3-month intervals up to Month 12 after discharge, if available. In addition, if a participant was discharged from the hospital prior to Day 28, attempts were made to collect additional scheduled assessments through Day 28 on an outpatient basis, if feasible. The ImmPort Study Accession ID for IMPACC is SDY1760, with additional proteomics data available in SDY2112.